BCAB Company Profile and Key Details

Q: Who are the executives of BCAB?

Dr. Eric L. Sievers M.D.Chief Medical OfficerMs. Susie MelodySenior Vice President of HRMr. Philippe MartinChief Clinical Devel. & OperationsMs. Monica SullivanSenior Vice President of Intellectual Property & ContractsDr. Jay M. Short Ph.D.Co-Founder, Chief Executive Officer & ChairmanDr. Cathy Chang Ph.D.Senior Vice President of R&DLisa M. PeltonAccounting Mang.Dr. Gerhard Frey Ph.D.Senior Vice President of Technology Devel.Ms. Sheri LydickSenior Vice President of Commercial StrategyMr. Richard A. WaldronSenior Vice President & Chief Financial OfficerMr. Christian VasquezSenior Vice President of Fin. & Sec.Mr. Christian J. VasquezSenior Vice President of Fin., Corporation Controller & Sec.Mr. Scott Andrew SmithChief Executive Officer & Director

NASDAQ : BCAB

BioAtla

$1.74

0.415+31.44%

At Close 4:00 PM

Not Actively Trading

56.94

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

BioAtla, Inc. (BCAB) stock surged +31.44%, trading at $1.74 on NASDAQ, up from the previous close of $1.32. The stock opened at $1.58, fluctuating between $1.58 and $2.06 in the recent session.

Stock Snapshot

1.32

Prev. Close

2.88M

Market Cap

1.58

Day Low

-0.12

P/E Ratio

-14.76

EPS (TTM)

-2.17

Cash Flow per Share

1.58

Open

1.66M

Number of Shares

2.06

Day High

77.36%

Free Float in %

1.47

Book Value

1.03M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Aug 28, 2026	1.58	2.10	1.51	1.74	1.03M
Aug 27, 2026	3.15	3.25	3.07	3.14	31.33K
Aug 26, 2026	3.35	3.37	3.06	3.12	21.44K
Aug 25, 2026	3.28	3.47	3.09	3.26	55.27K
Aug 24, 2026	3.27	4.00	3.10	3.28	392.61K
Aug 21, 2026	3.26	3.41	3.03	3.18	88.74K
Aug 20, 2026	3.24	3.35	3.14	3.18	18.77K
Aug 19, 2026	3.28	3.33	3.04	3.27	47.22K
Aug 18, 2026	3.01	3.25	2.98	3.18	30.22K
Aug 17, 2026	3.12	3.14	2.81	3.06	206.93K
Aug 14, 2026	3.43	3.50	3.00	3.09	143.74K
Aug 13, 2026	3.41	3.46	3.20	3.45	0
Aug 12, 2026	3.55	3.60	3.28	3.38	64.06K
Aug 11, 2026	3.56	3.56	3.37	3.50	45.23K
Aug 10, 2026	3.54	3.63	3.37	3.47	69.04K
Aug 07, 2026	3.33	3.71	3.27	3.46	37.09K
Aug 06, 2026	3.35	3.54	3.27	3.33	39.59K
Aug 05, 2026	3.64	3.70	3.27	3.33	44.46K
Aug 04, 2026	3.39	3.49	3.27	3.35	58.44K
Aug 03, 2026	3.38	3.45	3.15	3.26	46.67K

Contact Details

San Diego, CA 92121

United States

https://www.bioatla.com 858 558 0708

About Company

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.

Stock Peers

ARGX

-18.27-1.82%

argenx SE$984.04 REGN

-14.39-1.78%

Regeneron Pharmaceuticals, Inc.$793.26 MDGL

-13.54-2.48%

Madrigal Pharmaceuticals, Inc.$533.12 VRTX

-6.56-1.26%

Vertex Pharmaceuticals Incorporated$514.56 UTHR

-2.96-0.58%

United Therapeutics Corporation$503.86 KRYS

-2.54-0.73%

Krystal Biotech, Inc.$345.55 ONC

-9.2-2.62%

BeOne Medicines AG$341.80 PRAX

-6.73-1.95%

Praxis Precision Medicines, Inc.$338.57 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

1.2+0.42%

Ligand Pharmaceuticals Incorporated$289.25

Frequently Asked Questions

What is the current BioAtla, Inc. (BCAB) stock price?

BioAtla, Inc. (NASDAQ: BCAB) stock price is $1.74 in the last trading session. During the trading session, BCAB stock reached the peak price of $2.06 while $1.58 was the lowest point it dropped to. The percentage change in BCAB stock occurred in the recent session was 31.44% while the dollar amount for the price change in BCAB stock was $0.42.

BCAB's industry and sector of operation?

The NASDAQ listed BCAB is part of Biotechnology industry that operates in the broader Healthcare sector. BioAtla, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BCAB?

Dr. Eric L. Sievers M.D.
Chief Medical Officer
Ms. Susie Melody
Senior Vice President of HR
Mr. Philippe Martin
Chief Clinical Devel. & Operations
Ms. Monica Sullivan
Senior Vice President of Intellectual Property & Contracts
Dr. Jay M. Short Ph.D.
Co-Founder, Chief Executive Officer & Chairman
Dr. Cathy Chang Ph.D.
Senior Vice President of R&D
Lisa M. Pelton
Accounting Mang.
Dr. Gerhard Frey Ph.D.
Senior Vice President of Technology Devel.
Ms. Sheri Lydick
Senior Vice President of Commercial Strategy
Mr. Richard A. Waldron
Senior Vice President & Chief Financial Officer
Mr. Christian Vasquez
Senior Vice President of Fin. & Sec.
Mr. Christian J. Vasquez
Senior Vice President of Fin., Corporation Controller & Sec.
Mr. Scott Andrew Smith
Chief Executive Officer & Director

How BCAB did perform over past 52-week?

BCAB's closing price is 62.15% higher than its 52-week low of $1.07 where as its distance from 52-week high of $71.50 is -97.57%.

How many employees does BCAB have?

Number of BCAB employees currently stands at 41.

Link for BCAB official website?

Official Website of BCAB is: https://www.bioatla.com

How do I contact BCAB?

BCAB could be contacted at phone 858 558 0708 and can also be accessed through its website. BCAB operates from 11085 Torreyana Road, San Diego, CA 92121, United States.

How many shares of BCAB are traded daily?

BCAB stock volume for the day was 1.03M shares. The average number of BCAB shares traded daily for last 3 months was 77.67K.

What is the market cap of BCAB currently?

The market value of BCAB currently stands at $2.88M with its latest stock price at $1.74 and 1.66M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	41
Beta	0.76
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	41
Beta	0.76
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

BCAB Company Profile and Key Details

BioAtla

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Shareholding & Insider Activity

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics